Valuation: Patrys Limited

Market Cap 23.33M 16.33M 14.32M 13.23M 12.17M 22.96M 1.57B 158M 62.03M 771M 61.33M 59.99M 2.66B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 15.81M 13.86M 12.81M 11.78M 22.23M 1.52B 153M 60.05M 746M 59.38M 58.08M 2.57B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 day-7.69%
1 week-7.69%
Current month+2.86%
1 month-20.00%
3 months+44.00%
6 months+28.57%
Current year+28.57%
1 week 0.04
Extreme 0.036
0.04
1 month 0.03
Extreme 0.034
0.05
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.012
0.05
3 years 0.01
Extreme 0.012
0.13
5 years 0.01
Extreme 0.012
0.64
10 years 0.01
Extreme 0.012
0.91
Manager TitleAgeSince
Chief Executive Officer - 15/02/2026
Chief Operating Officer - 31/05/2012
Corporate Secretary - 09/11/2025
Director TitleAgeSince
Director/Board Member - 09/11/2025
Chairman 64 -
Director/Board Member - 16/06/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-7.69%-7.69%+200.00%-70.00% 18.2M
-0.03%-1.02%+55.98%+53.19% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+2.04%+2.20%+39.43%-4.08% 20.03B
-0.69%-1.67%+31.44%-34.30% 17.31B
-1.67%-6.00%+163.95%+284.69% 14.99B
+1.39%+2.37%+35.06%+584.56% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
Average -0.26%-0.89%+58.92%+146.54% 23.66B
Weighted average by Cap. +1.24%-0.93%+42.98%+133.19%

Financials

2024 2025
Net sales 1.39M 976K 855K 791K 727K 1.37M 94.11M 9.45M 3.71M 46.05M 3.66M 3.58M 159M 829K 580K 508K 470K 432K 815K 55.93M 5.62M 2.2M 27.37M 2.18M 2.13M 94.28M
Net income -3.54M -2.48M -2.17M -2.01M -1.85M -3.48M -239M -24M -9.41M -117M -9.3M -9.1M -403M -3.01M -2.11M -1.85M -1.71M -1.57M -2.97M -203M -20.44M -8.01M -99.53M -7.92M -7.75M -343M
Net Debt -2.24M -1.57M -1.37M -1.27M -1.17M -2.21M -151M -15.2M -5.96M -74.01M -5.89M -5.76M -255M -742K -520K -456K -421K -387K -731K -50.12M -5.04M -1.97M -24.52M -1.95M -1.91M -84.49M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
21/07/26 A$0.0360 -7.69% 578,139
20/07/26 A$0.0390 +2.63% 556,942
17/07/26 A$0.0380 0.00% 106,374
16/07/26 A$0.0380 0.00% 4,452
15/07/26 A$0.0380 -2.56% 217,121